Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol.
Andres Ramos-FresnedoRawan Al-KharbooshErin L TwohyAleeshba N BasilEwa C SzymkiewiczAbba C ZubairDaniel M TrifilettiNisha DurandDennis W DicksonErik H MiddlebrooksDavid N AbarbanelStephany Y TzengJoao Paulo AlmeidaKaisorn L ChaichanaJordan J GreenWendy J ShermanAlfredo Quiñones-HinojosaPublished in: Neurosurgery practice (2023)
This prospective translational study will determine the initial safety and toxicity profile of local delivery of AMSCs for recurrent GBM. It will also provide additional survival metrics for future randomized trials.